Figure 4
Figure 4. Effects of AMI-coated liposomes on the time course of MWReg30-mediated thrombocytopenia. MWReg30 was administered by intraperitoneal infusion (0.99 μg/d × 7 days). AMI-coated liposomes were given by intravenous bolus injection at 96 hours, and platelet counts were obtained using a Cell-Dyn 1700 multiparameter hematology analyzer. Symbols represent the sham control group (▾) and animals treated with saline (•), 15 μmol lipid/kg (▪), 30 μmol lipid/kg (♦), or 60 μmol lipid/kg (▴) (n = 5 mice/group). Error bars represent the standard deviation of platelet count values. AMI-coated liposomes attenuated MWReg30-mediated thrombocytopenia in a dose-dependent manner. Treatment differences were statistically significant (P < .001).

Effects of AMI-coated liposomes on the time course of MWReg30-mediated thrombocytopenia. MWReg30 was administered by intraperitoneal infusion (0.99 μg/d × 7 days). AMI-coated liposomes were given by intravenous bolus injection at 96 hours, and platelet counts were obtained using a Cell-Dyn 1700 multiparameter hematology analyzer. Symbols represent the sham control group (▾) and animals treated with saline (•), 15 μmol lipid/kg (▪), 30 μmol lipid/kg (♦), or 60 μmol lipid/kg (▴) (n = 5 mice/group). Error bars represent the standard deviation of platelet count values. AMI-coated liposomes attenuated MWReg30-mediated thrombocytopenia in a dose-dependent manner. Treatment differences were statistically significant (P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal